Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06382155 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 22, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 2 of 47 sitesv6
  2. Eligibility criteria expanded, about 36 words
    • Secondary endpoints revised (18)
    • Study description expanded, about 130 words
    v5
  3. Study sites: 8 to 47
    • Secondary endpoints revised (18)
    v4
  4. Study sites: 2 to 8v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2024 to Oct 21, 2024
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate i) the effect of multiple doses of vosoritide and ii) the effect of the therapeutic dose of vosoritide compared to human growth hormone (hGH)(hGH; only in the United States), in children with idiopathic short stature (ISS).
Trial Details
NCT Number NCT06382155
Lead Sponsor BioMarin Pharmaceutical
Conditions
(from sponsor)		 Idiopathic Short Stature
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov